These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20143007)

  • 21. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
    Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
    Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recommendations on the use of rituximab for patients with rheumatoid arthritis].
    Rubbert-Roth A; Burmester G;
    Z Rheumatol; 2008 Nov; 67(7):609-13. PubMed ID: 18830700
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety issues related to emerging therapies for rheumatoid arthritis.
    Keystone EC
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S148-50. PubMed ID: 15552529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
    Jacobi AM; Dörner T
    Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
    N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
    Faurschou M; Jayne DR
    Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
    Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
    Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
    Dass S; Vital EM; Emery P
    Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
    Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2418-23. PubMed ID: 19149039
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
    Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
    Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab - shadow, illusion or light?
    van Vollenhoven RF
    Autoimmun Rev; 2012 Jun; 11(8):563-7. PubMed ID: 22036829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.
    Trouvin AP; Jacquot S; Grigioni S; Curis E; Dedreux I; Roucheux A; Boulard H; Vittecoq O; Le Loët X; Boyer O; Goëb V
    Clin Exp Immunol; 2015 Apr; 180(1):11-8. PubMed ID: 25370437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.